Tue, Jul 22, 2014, 10:59 AM EDT - U.S. Markets close in 5 hrs 1 mins

Recent

% | $
Click the to save as a favorite.

Crestwood Midstream Partners LP Message Board

twojugglers 100 posts  |  Last Activity: 15 hours ago Member since: Apr 6, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • twojugglers twojugglers 15 hours ago Flag

    The author gave Onvo a rather unfair comment about profitability.

    "Biotechnology company Organovo (NYSE: ONVO) is already bio-printing human tissue for research and therapeutic purposes, but it remains focused on much simpler structures such as liver and bone. And even with these less complicated structures, the company is finding it impossible to turn a profit."

    What the H...?

    Sentiment: Strong Buy

  • Reply to

    Short positions

    by e7navy1999 Jul 19, 2014 6:16 PM
    twojugglers twojugglers Jul 20, 2014 10:46 AM Flag

    From the Short Analytics website they show a huge increase in recent short positions. If this is true we have phase II of the Short and Distort campaign to look forward to.


    Date Symbol Name Short Volume Long Volume Total Volume Short%
    2014-07-18 ONVO Organovo Holdings 319825 173416 493241 65
    2014-07-17 ONVO Organovo Holdings 286660 381418 668078 43
    2014-07-16 ONVO Organovo Holdings 236703 269292 505995 47
    2014-07-15 ONVO Organovo Holdings 356560 449877 806437 44
    2014-07-14 ONVO Organovo Holdings 117842 205798 323640 36
    2014-07-11 ONVO Organovo Holdings 98488 191107 289595 34
    2014-07-10 ONVO Organovo Holdings 228241 600467 828708 28

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 18, 2014 6:54 PM Flag

    Follow,

    Not sure if FDA gets involved in their toxicity testing. How do you see that playing out?

    Juggsy

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 18, 2014 4:06 PM Flag

    m,

    I agree.

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 18, 2014 3:24 PM Flag

    Over 100,000 shares traded during that brief spike.

    Sentiment: Strong Buy

  • Rated Organovo "Long" and as a "Buy" on June 9, 2014.

    Sentiment: Strong Buy

  • Reply to

    "Scientists running out of tissue"

    by pierre_narusse Jul 17, 2014 10:30 AM
    twojugglers twojugglers Jul 17, 2014 10:52 AM Flag

    Can't find that article. Where is it published?
    Thanks,
    Juggsy

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 15, 2014 10:20 PM Flag

    Or maybe its 39%. You may be closer to right on that.

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 15, 2014 10:19 PM Flag

    ckelly,

    Yep, and possibly more. I'm actually estimating a tax bracket of 49% this year. I've sent in some large estimated tax payments so far, but the tax law allows me 1 year to get with the program in that regard, so I'm anticipating a large payment at tax time too.

    What I've made on KNDI calls is absolutely amazing. Their premiums are the highest I've seen. Today for example, If one had bought KNDI when it was trading for $19.25 and immediately sold $20.00 August calls, the return on that trade would have been 9%. It looks like the $15.00 July calls I'm short will be called out this Friday. If I take my cash Monday and buy back in and sell August calls, I stand a good chance of making 8% on that trade. MInd you, right now it looks like I would have done better not selling any calls at all :(.

    All the best,

    Juggsy

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 15, 2014 9:16 PM Flag

    Good plan Navy. I'm going to have a large tax liability for all the calls I've sold. But then, that's not a terrible problem to have :)

    If I take options sales into consideration as lowering my cost basis, then I'm down to $1.61 average cost for my ONVO shares. Sweet.

    Best,

    Juggsy

    Sentiment: Strong Buy

  • twojugglers by twojugglers Jul 15, 2014 9:04 PM Flag

    I wonder which one will volunteer to to get sued this time for writing a totally inaccurate and defaming article?

    Sentiment: Strong Buy

  • Reply to

    Juggsy

    by lovemyonvo Jul 14, 2014 2:07 PM
    twojugglers twojugglers Jul 14, 2014 10:12 PM Flag

    gpls,

    Its thanks to you that KNDI has been very good to me. This recent event is just a minor setback. If I get called at at $15.00, I will have made enough since last December to consider it all a good experience.
    Good luck to you.

    Juggsy

    Sentiment: Strong Buy

  • Reply to

    Juggsy

    by lovemyonvo Jul 14, 2014 2:07 PM
    twojugglers twojugglers Jul 14, 2014 3:45 PM Flag

    Hi Love,

    Sure hope that works out for you too, along with you $9.00 calls. I know there are a lot of happy call holders on the KNDI board today. Me not included. I'm short quite a few $15.00 calls.

    Our day will come here too. Just not today.

    Juggsy

    Sentiment: Strong Buy

  • twojugglers by twojugglers Jul 14, 2014 8:43 AM Flag

    Well Done
    Over Hard
    Burnt
    Crispy

    Sentiment: Strong Buy

  • Reply to

    Buckle Up

    by ajaffster Jul 10, 2014 8:43 AM
    twojugglers twojugglers Jul 13, 2014 11:17 AM Flag

    blakem,

    This is from ONVO's most recent annual report:

    "At March 31, 2014, we had total current assets of $49.2 million and current liabilities of $1.9 million, resulting in working capital of $47.3
    million. ...

    .... The majority of net cash used in investing activities from inception to date has been for the purchases of
    equipment for the research lab.


    Net cash provided by financing activities was approximately $48.4 million, ....
    for the year ended March 31, 2014,
    During the year ended March 31, 2014, we raised net proceeds of approximately $43.4 million through the sale of 10,350,000 shares of our
    common stock in a public offering. In addition, we raised net proceeds of approximately $3.5 million from an at-the-market follow-on offering,
    $1.0 million from the exercise of warrants, and $0.4 million from stock option exercises during the year ended March 31, 2014. .....

    .Through March 31, 2014, the Company has financed its operations primarily through the sale of convertible notes, the private placement of
    equity securities, the public offering of common stock, and through revenue derived from grants and collaborative research agreements. . Based
    on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve
    months. "

    If you have time to read the most recent annual report, I highly recommend it.

    All the best,

    Juggsy

    Sentiment: Strong Buy

  • Reply to

    Buckle Up

    by ajaffster Jul 10, 2014 8:43 AM
    twojugglers twojugglers Jul 12, 2014 10:15 PM Flag

    Followme,

    Looking 6 years ahead, how would you value a company like Organovo that could take a patient's own cells and print a tissue patch that would improve that patient's liver function, with little chance of rejection? And before that, could replicate a patient's cancerous breast tissue so as to allow a pharmaceutical company or cancer treatment team to tailor a drug regimen to maximize effectiveness for each individual patient. And even before that could provide liver tissue for new drug testing to large Pharmas around the world, saving them millions in wasted drug development costs? ...Who already has first rights to license recently-announced technology that can create vascular pathways in printed tissue. Who has a very reasonable share structure and enough money in the bank to carry them into profitability.

    I'd value them on revenue potential, not overall market gyrations. IMHO, it won't be long before we see a Dendreon-like escalation in PPS. I wouldn't be waiting for a drop in price if I sincerely wanted more shares.

    Juggsy

    Sentiment: Strong Buy

  • Reply to

    Possible KOL Presentation?

    by bomba_travel Jul 11, 2014 10:21 AM
    twojugglers twojugglers Jul 12, 2014 5:42 PM Flag

    bomba,

    I've scoured the ISSX website and don't see anything related to Organovo. But, the whole purpose of ISSX, the International Society for the Study of Xenobiotics is so closely aligned with drug toxicity that Organovo is the perfect fit for them:

    "ISSX is one of the largest scientific societies dedicated to investigating the metabolism and disposition of chemicals in biological systems. The Society’s activities are relevant to all aspects of drug development and toxicology worldwide. The strength of the organization is its international nature as well as the breadth of the membership’s interests.

    The study of xenobiotics (medicinal drugs, agricultural chemicals, industrial chemicals, environmental contaminants and other exogenous substances) encompasses the introduction into, distribution and transport throughout, interactions with and elimination of these compounds from biological systems. The studies on xenobiotics include the rates and extents of the processes and the biological consequences."

    I'm really looking forward to finding out just what Organovo will present.

    Juggsy

    Sentiment: Strong Buy

  • The link to this article is on the front page of Organovo's website:

    3D Bioprinting Could Speed Up Drug Development

    Just two snippets:

    "While Murphy admits that no test can be 100 percent accurate, he says 3D bioprinting represents a huge leap forward from animal testing and Petri dishes. For example, he says the small tissue being created is indeed representative of the larger tissue. "We are starting from a place where it's so bad that slight improvements are incredibly good, and we're creating what we think is a dramatic improvement," he says. "We may fall short of being perfect, but we are so much closer to perfect than the available methods that the benefit is huge." "

    "Organovo is about six years away from entering clinical studies to make tissues for surgical implant. "Everyone quickly thinks about large organs; bioprint an organ and implant it into the body. But, instead, we are focused a little smaller. Think of a 3D bioprinted liver patch to help repair a damaged liver. We could take cells from the patient to create the patch, which would almost assure no immune response."

    The applications and the implications are plentiful. Organovo will continue to work with liver and kidney tissue, but other 3D bioprinting research will include oncology, lung tissue, muscle tissue, and blood vessels."

    Just imagine the implications for Organovo when they are able to provide liver patches with a patient's own cells.....

    Or when a person on dialysis can be relieved of that burden.....

    Amazing.

    Sentiment: Strong Buy

  • July 11, 2014
    Dear Stockholder:
    You are cordially invited to attend this year’s annual meeting of stockholders of Organovo Holdings, Inc. on Wednesday, August 20, 2014 at 9:00 a.m. (local time). The meeting will be held at our corporate offices located at 6275 Nancy Ridge Dr., Suite 110, San Diego, California 92121.

    Wish I could go. If any of you go, please do some "Shake and Howdy" for me.

    Thanks,

    Juggsy

    Sentiment: Strong Buy

  • BIO 2014: Innovations in 3-D Tissue for Disease and Drug Discovery

    Brief 2-page article written by Sharon Pressnall and published in Xconomy. Worth a read.

    Juggsy

    Sentiment: Strong Buy

CMLP
23.35-0.08(-0.34%)10:58 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.